Meta AnalysisID 1962
抗组胺药难治性慢性自发性荨麻疹治疗方法的比较有效性和可接受性：随机对照试验和观察性研究的网状Meta分析
CRD42020196592
To investigate the effects of different treatment strategies on efficacy and acceptability of treatment among adolescent and adult patients with antihistamine-resistant chronic spontaneous urticarial (CSU) through a syst
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1962
- Evidence Id
- 10520
- Core Evidence Id
- 10520
- Source Meta Analysis Id
- 1907
- Herb2 Meta Analysis Id
- HBMA001907
- Crd Id
- CRD42020196592
- Title
- Comparative Effectiveness and Acceptability of Treatments for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Network Meta-Analysis of Randomized Controlled Trials and Observational Studies
- Review Question
- To investigate the effects of different treatment strategies on efficacy and acceptability of treatment among adolescent and adult patients with antihistamine-resistant chronic spontaneous urticarial (CSU) through a systematic review and meta-analysis, including a network meta-analysis.
- Study Type Included
- Published randomized controlled trials (RCTs), quasi-RCT, and comparative effectiveness observational studies (cohort studies) in any setting and context. Crossover, case-control, cross-sectional, N of one trial, and case series/case reports will be excluded.
- Condition Being Studied
- Antihistamine-refractory CSU.
- Participant
- Adolescents or adults (12 years or older) diagnosed with antihistamine-refractory CSU.
- Animal
- Human Disease Modelled
- Intervention
- Treatment with any type of administered treatments for antihistamine-refractory CSU: anti-immunoglobulin E (IgE) therapy (e.g. omalizumab, ligelizumab), other monoclonal antibodies therapy (e.g. rituximab, anakinra, anti-tumor necrosis factor-alpha), interferon alpha, protease inhibitors (e.g. camostat mesylate, nafamostat mesylate), immunosuppressive agents (e.g. cyclosporine, tacrolimus, sirolimus, methotrexate, azathioprine, mycophenolic acid), leukotriene receptor antagonists (montelukast, zafirlukast), histamine-2 antihistamines (e.g. cimetidine, ranitidine), miltefostine, vitamin D3, anti-inflammatory agents (hydroxychloroquine, dapsone, sulfasalazine, colchicine), oral corticosteroids, intravenous immunoglobulin (IVIG), plasmapheresis, anticoagulant (e.g. heparin, warfarin) ketotifen, androgens (e.g. danazol, stanozol), tranexamic acid, doxepin, serotonin reuptake inhibitors (SSRIs), mirtazapine, pseudoallergen-free diet, autologous blood/serum, holistic medicine, and phototherapy.
- Comparator Control
- Non-users (no treatment), placebo, active comparator, or standard care.
- Main Outcome
- (i) Change in CSU disease activity (e.g. urticaria activity score, angioedema activity score, total symptom score, pruritus score, number of wheal score) (ii) Treatment response (iii) Acceptability of treatment (all-cause discontinuation) Measures of effect Mean changes from baseline, the incidence of the outcome of interests, hazard ratios (HRs), risk ratios (RRs), odds ratios (ORs): All-time points as defined by the specific studies.
- Outcome Measure
- Additional Outcome
- (i) Health-related quality of life (ii) Biomarkers of CIU/CSU activity (iii) Discontinuation of treatment due to adverse events/serious hospitalization sequelae (iv) Incidence of adverse events (v) Treatment failure (lack of efficacy or need for rescue treatment) Measures of effect Mean changes from baseline, the incidence of the outcome of interests, hazard ratios (HRs), risk ratios (RRs), odds ratios (ORs): All-time points as defined by the specific studies.
- Study Method
- Meta-analysis, Network meta-analysis, Systematic review
- Keyword
- Humans
- Contact
- Mati Chuamanochan [email protected]
- Organisational Affiliation
- Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand
- Funding Source
- Partially supported by Chiang Mai University.
- Other Selection Criteria
- Final Publication
- 1) Nochaiwong S, Chuamanochan M, Ruengorn C, Awiphan R, Tovanabutra N, Chiewchanvit S. Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis. JAMA Dermatol. 2021 Nov 1;157(11):1316-1327. 2) Nochaiwong S, Chuamanochan M, Ruengorn C, Awiphan R, Tovanabutra N, Chiewchanvit S, Hutton B, Thavorn K. Impact of Pharmacological Treatments for Chronic Spontaneous Urticaria with an Inadequate Response to H1-antihistamines on Health-Related Quality of Life: A Systematic Review and Network Meta-Analysis. J Allergy Clin Immunol Pract. 2021 Oct 22:S2213-2198(21)01141-7. doi: 10.1016/j.jaip.2021.10.022. Epub ahead of print.
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Thailand
- Review Stage
- Review Completed published being updated
- First Submission Date
- 2020-07-02
- Registration Date
- 2020-08-01
- Anticipated Start Date
- 2020-06-30
- Anticipated Completion Date
- 2024-10-31
- Title Cn
- 抗组胺药难治性慢性自发性荨麻疹治疗方法的比较有效性和可接受性：随机对照试验和观察性研究的网状Meta分析
- Title En
- Comparative Effectiveness and Acceptability of Treatments for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Network Meta-Analysis of Randomized Controlled Trials and Observational Studies
- Bilingual Status
- complete